Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TOCOSOL Paclitaxel · 2 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| TOCOSOL Paclitaxel | EXPERIMENTAL | TOCOSOL Paclitaxel administered weekly at 120mg/mm2 |
| Name | Type | Description |
|---|---|---|
| TOCOSOL(R) Paclitaxel | DRUG | - |
| TOCOSOL Paclitaxel | DRUG | - |
Inclusion Criteria: * Female patient with histologic diagnosis of breast carcinoma * Stage IV (M1) disease * No prior cytotoxic chemotherapy regimen for treatment of metastatic breast cancer * Adult (18 years of age or older) patients * Adequate hematologic function (ANC \>=1500 cells/mm3 and plate...
TOCOSOL Paclitaxel is an investigational small molecule being studied for the treatment of bladder neoplasms and breast cancer. It has been evaluated in clinical trials for metastatic or locally advanced unresectable transitional cell carcinoma of the urothelium and as initial treatment for metastatic breast cancer.
TOCOSOL Paclitaxel is being developed by Achieve Life Sciences, Inc., a company traded on the NASDAQ under the ticker symbol ACHV. The drug is currently in Phase 2 clinical development for oncology indications.
TOCOSOL Paclitaxel is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials for this drug have been completed, and it remains under investigation for its safety and efficacy.
TOCOSOL Paclitaxel has been studied in two completed Phase 2 trials. One trial, NCT00077688, enrolled 44 participants with bladder, ureteral, or urethral neoplasms and transitional cell carcinoma in the United States. Another trial, NCT00096668, enrolled 47 female participants with breast cancer in Russia.
TOCOSOL Paclitaxel is a formulation of paclitaxel, a chemotherapy agent. It is being developed as a specific product by Achieve Life Sciences. The clinical trials listed for TOCOSOL Paclitaxel evaluate it as a treatment for bladder cancer and breast cancer.